Skip to main content

Table 1 Summary of key assumptions considered in the cost-effectiveness model

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

Parameter Key assumptions
Model structure Two-stage Markov cohort model
CE model time horizon Lifetime
Model cycle Monthly
CV mortality for SoC SHIFT data by applying Gompertz survival model
HR for CV mortality of ivabradine vs SoC 0.90 (0.80 – 1.03) based on SHIFT data
Rate hospitalization SHIFT data by applying Poisson model
Rate ratio for hospitalization of ivabradine vs SoC 0.83 (0.78 – 0.93) based on SHIFT data
Length of hospitalization Local data (based on experts’ opinion)
Utility data SHIFT data by applying mixed regression model
NYHA data SHIFT data by applying adjusted ordered logistic regression
Ivabradine treatment effect Cardiovascular endpoint
Ivabradine use (years) Lifelong
Cost discount rate per annum 3.5%
Effects discount rate per annum 3.5%
Resource utilization and unit costs Local data (government gazette and experts’ opinion)
Outcome mesaures QALYs, LYs, ICER per QALY and per LY gained, lifetime total cost
  1. CE: cost-effectiveness; HR: hazard ratio; QALYs: quality-adjusted life years; LYs: life years; ICER: incremental cost effectiveness ratio; CV: cardiovascular; NYHA: New York Heart Association.